

AD\_\_\_\_\_

Award Number: DAMD17-01-1-0670

TITLE: Beta IV Spectrin in Normal and Cancer Breast Cells

PRINCIPAL INVESTIGATOR: Pietro De Camilli, M.D.

CONTRACTING ORGANIZATION: Yale University School of Medicine  
New Haven, Connecticut 06520-8047

REPORT DATE: September 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031114 076

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> September 2002	<b>3. REPORT TYPE AND DATES COVERED</b> Final (1 Sep 2001 - 31 Aug 2002)	
<b>4. TITLE AND SUBTITLE</b> Beta IV in Normal and Cancer Breast Cells			<b>5. FUNDING NUMBERS</b> DAMD17-01-1-0670	
<b>6. AUTHOR(S)</b> Pietro De Camilli, M.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Yale University School of Medicine New Haven, Connecticut 06520-8047  E-Mail: Pietro.decamilli@yale.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b> Original contains color plates: All DTIC reproductions will be in black and white.				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> Long-term goal of this application was to elucidate pathogenetic mechanisms in human autoimmune paraneoplastic neurological conditions. These syndromes result from the ectopic expression in cancer cells of neuronal antigens followed by the onset of an autoimmune response directed at the cancer tissue. A side effect of this response is an autoimmune impairment of nervous system function. We have identified novel autoantigens of autoimmune paraneoplastic conditions, primarily autoantigens expressed in breast cancer. Recently, we have identified a woman with lower motor neuron syndrome, breast cancer and anti- $\beta$ IV spectrin autoantibodies. The specific goal of this project was to conduct studies on the properties of $\beta$ IV spectrin and to determine whether anti- $\beta$ IV spectrin antibodies are a frequent occurrence in cancer. If this was the case, such antibodies could be used as diagnostic tools and $\beta$ IV spectrin could represent a target for cancer immunotherapy. We have made progress towards the elucidation of $\beta$ IV spectrin function and expression profile. A $\beta$ IV mutant mouse was generated and found to have significant neurological defects, consistent with a critical role of this protein in axonal physiology. However, so far we have failed to obtain evidence for the occurrence of widespread anti- $\beta$ IV spectrin autoimmunity in cancer patients.				
<b>14. SUBJECT TERMS</b> Stiff-Person Syndrome, Beta IV Spectin, Breast Cancer, Antibodies, Autoimmunity				<b>15. NUMBER OF PAGES</b> 26
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	6
References.....	6
Appendices.....	7

## Introduction

Long-term goal of the project was the elucidation of autoimmune immune mechanisms in cancer with the expectation that such studies will make possible the development of diagnostic tools for the early detection of cancer as well of immuno-therapeutic strategies for its cure. The rationale of the application was to capitalize on the occurrence of autoimmune paraneoplastic neurological conditions to improve our understanding of autoimmunity in cancer. These are human syndromes in which the ectopic expression in cancer of neuronal antigens, or of neuronal splice variants of ubiquitously expressed proteins, leads to autoimmune attack of cancer tissue that often delays its progression. The same attack, however, also results in an autoimmune impairment of the nervous system function. An attractive possibility is that the ectopic autoantigen may not only trigger autoimmunity but also play a role in the biology of cancer cells. Our lab has identified novel paraneoplastic autoantigens and paraneoplastic syndromes. For example, we have defined a syndrome characterized by breast cancer, Stiff-Man syndrome and autoantibodies directed against the neuronal protein amphiphysin. In some of these patients our detection of anti-amphiphysin antibodies has prompted the search for, and detection of, an occult breast cancer. Recently, we have identified a patient with breast cancer, Lower Motor Neuron Disease and autoimmunity to  $\beta$ IV spectrin. Upon removal of the cancer there was a 70% reduction in the titer of anti- $\beta$ IV spectrin autoantibodies and a dramatic improvement of the neurological symptoms, confirming that the cancer tissue was driving the autoimmune response.  $\beta$ IV spectrin a member of the spectrin family of plasma membrane associated proteins, which is expressed as alternatively spliced isoforms in a variety of tissues including brain. A major brain isoform of  $\beta$ IV spectrin is present at axon initial segments and nodes of Ranvier where it may participate in the localization and concentrations of  $\text{Na}^+$  channels. This project had two specific aims: 1) the characterization of the expression of  $\beta$ IV spectrin in normal and neoplastic tissue and 2) the screen of a large population of breast cancer patients for the presence of anti- $\beta$ IV spectrin antibodies.

## Body

We have pursued studies on the cell biology of  $\beta$ IV spectrin and on the potential connection of this protein to cancer.

We have generated a mouse that selectively lacks the longer  $\beta$ IV spectrin transcript (the 250 kD isoform corresponding to  $\beta$ IV $\Sigma$ 1 spectrin). All other  $\beta$ IV spectrin isoforms, which are smaller in size, were still detectable by immunoblot. These data confirm our hypothesis that such polypeptides do not originate from the proteolysis of  $\beta$ IV $\Sigma$ 1 spectrin, but represent alternatively spliced variants of the gene (Berghs et al., 2002).  $\beta$ IV $\Sigma$ 1 spectrin  $-/-$  mice are moderately hyperactive, and display intention tremor and mild dysmetria, consistent with cerebellar impairment and possibly some degree of abnormal myelination. The lack of  $\beta$ IV $\Sigma$ 1 spectrin correlates with a reduced immunoreactivity for  $\text{Na}^+$  channels at nodes of Ranvier and with a broader distribution of  $\text{K}^+$  channels in the adjacent paranodal regions (Lacas-Gervais et al., abstract for the ELSO Meeting 2003; manuscript in preparation). These changes may explain the deficit in nerve conduction that has also been observed in two other independently described  $\beta$ IV spectrin  $-/-$  mice (Parkinson et al., 2001; Komada and Soriano, 2002), both of which lack multiple  $\beta$ IV spectrin isoforms. Our data, however, are the first to prove that the  $\beta$ IV $\Sigma$ 1 spectrin is the specific spectrin isoform expressed at nodes of Ranvier and that the absence of this isoform is sufficient to induce neurological alterations previously observed in

$\beta$ IV spectrin  $-/-$  mice. Taken together, these findings are consistent with a potential role of anti- $\beta$ IV spectrin autoimmunity in the generation of paraneoplastic neurological symptoms in the patient we have investigated.

$\beta$ IV $\Sigma$ V spectrin is a 70 kD spliced variant of  $\beta$ IV spectrin that has been previously found in the nuclear bodies enriched in the acute promyelocytic leukemia (PML) protein, henceforth termed PML bodies (Tse et al., 2001). It has been suggested that PML bodies participate in the regulation of gene expression and/or protein degradation in the nucleus. We have now shown that other  $\beta$ IV spectrins are present in the nucleus and near the nuclear envelope. The small ubiquitin-like modifier SUMO and the SUMO ligases of the PIAS family are enriched in the PML bodies and several components of the PML bodies undergo sumoylation. Sumoylation has been also shown to modulate the nuclear import of cytosolic proteins. Interestingly, we identified  $\beta$ IV spectrin as an interactor of the receptor tyrosine phosphatase like-protein ICA512 and we have shown that the cytoplasmic domain of ICA512 binds the SUMO ligase PIAS $\gamma$ . A possible role of  $\beta$ IV spectrin in gene regulation is consistent with a potential function of this protein in the biology of cancer cells.

Concerning the second specific aim, i.e. the screen of a large population of cancer patients for the occurrence of anti- $\beta$ IV spectrin autoantibodies, we lowered its priority because of the lack of sufficiently strongly preliminary results suggesting the presence of anti- $\beta$ IV spectrin autoantibodies in the cancer population at large. Eventually, we did not have time to pursue it.

Support of this grant has indirectly supported additional studies on paraneoplastic autoimmunity. A case study on a patient with breast cancer, Stiff-Man syndrome, autoimmunity directed against amphiphysin and rhabdomyolysis (an amphiphysin isoform is highly expressed in skeletal muscle) is appended to this report.

### **Key research accomplishments**

- Generation and characterization of  $\beta$ IV $\Sigma$ 1 spectrin  $-/-$  mice
- Demonstration of  $\beta$ IV $\Sigma$ 1 as the specific spectrin isoform expressed at nodes of Ranvier
- Identification of a novel paraneoplastic condition associated with breast cancer

### **Reportable outcomes**

#### *Manuscripts*

Lacas-Gervais S\*, Guo J\*, Knoch K-P, Rasband M, De Camilli P and Solimena M. 2003. Deletion of  $\beta$ IV $\Sigma$ 1 spectrin alters the organization of nodes of Ranvier and is sufficient to produce the "quivering" phenotype in mice (manuscript in preparation). \* equal contributors.

Petzold GC, Marcucci M, Butler MH, van Landeghem, FKH, Scholz P, Einhäupl KM, Solimena M, Valdueza JM and De Camilli P. 2003. Recurrent rhabdomyolysis in a patient with Stiff-Person (Stiff-Man) syndrome associated with breast cancer and autoimmunity to amphiphysin (The manuscript, see appendix, will be submitted within the next 2-3 weeks)

#### *Abstracts*

Lacas-Gervais S\*, Guo J\*, Knoch K-P, Rasband M, De Camilli P and Solimena M. 2003. Quivering

- phenotype and altered distribution of  $K^+$ -channels in  $\beta IV\Sigma 1$  spectrin KO mice. Abstract to the ELSO Meeting, September 2003, France \* equal contributors (see appendix).

Yang Y, Lacas-Gervais S, Morest K, Solimena M, Rasband MN. Deletion of the specific and PH of  $\beta IV$  spectrin results in disrupted nodes of Ranvier. Abstract to the Society for Neuroscience Meeting, November 2003 (see appendix).

*Development of cell lines, tissue etc.*

*Generation of  $\beta IV\Sigma 1$  spectrin  $-/-$  mice*

Development of antibodies specific against  $\beta IV$  spectrin isoforms (anti- $\beta IV\Sigma 1/\beta IV\Sigma 2$ , anti- $\beta IV\Sigma 3$ , anti- $\beta IV\Sigma 4$ )

*Funding applied for partially based on support by this award:* we have successfully applied for a competitive renewal of an NCI Program project grant (project #1 P01 CA46128) focused on the study of the actin-based cytoskeleton in the biology of cancer cells. This grant cover the period 1-1-03/12-31-08.

## Conclusions

We have conclusively shown that  $\beta IV\Sigma 1$  spectrin, i.e. the main target of autoimmunity in the patient with breast cancer and paraneoplastic lower motor neuron syndrome, is a main component of nodes of Ranvier. The properties of  $\beta IV$  spectrin are consistent with its pathogenetic link to the neurological symptoms.

## References

- Berghs S, Ferracci F, Maksimova E, Gleason S, Leszczynski N, Butler M, De Camilli P, and Solimena M. 2001. Autoimmunity to  $\beta IV$  spectrin in paraneoplastic lower motor neuron syndrome. *Proc. Nat. Acad. Sci.* 98: 6945-6950.
- Berghs S, Aggujaro D, Dirkx R Jr, Maksimova E, Stabach P, Hermel JM, Zhang JP, Philbrick W, Slepnev V, Ort T, Solimena M. 2000. beta-IV spectrin, a new spectrin localized at axon initial segments and nodes of ranvier in the central and peripheral nervous system. *J Cell Biol.* 151:985-1002.
- Parkinson NJ, Olsson CL, Hallows JL, McKee-Johnson J, Keogh BP, Noben-Trauth K, Kujawa SG, Tempel BL. 2001. Mutant beta-spectrin 4 causes auditory and motor neuropathies in quivering mice. *Nat Genet.* 29:61-5.
- Komada M, Soriano P. 2002. BetaIV-spectrin regulates sodium channel clustering through ankyrin-G at axon initial segments and nodes of Ranvier. *J Cell Biol.* 156:337-48.
- Tse WT, Tang J, Jin O, Korsgren C, John KM, Kung AL, Gwynn B, Peters LL, Lux SE. 2001. A new spectrin, beta IV, has a major truncated isoform that associates with promyelocytic leukemia protein nuclear bodies and the nuclear matrix. *J Biol Chem.* 276:23974-85.

## **Appendices**

- Appendix 1 Manuscript (Petzold et al.)
- Appendix 2 Abstract Lacas-Gervais
- Appendix 3 Abstract Yang
- Appendix 4 Curriculum vitae of Dr. Pietro De Camilli (PI)
- Appendix 5 Curriculum vitae of Dr. Michele Solimena (PI of the original application; the grant was transferred to Dr. De Camilli when Dr. Solimena left Yale)

# Appendix 1

***THIS MANUSCRIPT WILL BE SUBMITTED WITHIN THE NEXT COUPLE OF WEEKS  
(5/27/03)***

## **RECURRENT RHABDOMYOLYSIS IN A PATIENT WITH STIFF-PERSON (STIFF-MAN) SYNDROME ASSOCIATED WITH BREAST CANCER AND AUTOIMMUNITY TO AMPHIPHYSIN.**

**Gabor C. Petzold, M.D.\*<sup>1,2</sup>, Melissa Marcucci, M.A.<sup>3</sup>, Margaret H. Butler, Ph.D.<sup>3</sup>, Frank K. H. van Landeghem, M.D.<sup>4</sup>, Peter Scholz, M.D.<sup>5</sup>, Karl M. Einhäupl, M.D.<sup>1</sup>, Michele Solimena, M.D., Ph.D.<sup>6</sup>, José M. Valdueza, M.D.<sup>1</sup>, Pietro De Camilli, M.D.\*<sup>3</sup>**

**Departments of <sup>1</sup>Neurology, <sup>2</sup>Experimental Neurology and <sup>4</sup>Neuropathology, Charité Hospital, Humboldt University, Schumannstr. 20/21, 10098 Berlin, Germany. <sup>3</sup>Howard Hughes Medical Institute and Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510, USA. <sup>5</sup>Department of Pathology, Rüdersdorf Hospital, 15562 Rüdersdorf, Germany. <sup>6</sup> Experimental Diabetology, University of Technology - Dresden, Fiedlerstrasse 74, Dresden 01307, Germany**

**\*Corresponding Authors: Pietro De Camilli, M.D., Howard Hughes Medical Institute and Department of Cell Biology, Yale University School of Medicine, New Haven, Connecticut 06510, USA. Phone: (203) 737-4461, Fax (203) 737-4436, e-mail: [pietro.decamilli@yale.edu](mailto:pietro.decamilli@yale.edu)**

**Gabor C. Petzold, M.D., Departments of Neurology and Experimental Neurology, Charité Hospital, Humboldt University, Schumannstr. 20/21, 10098 Berlin, Germany.**

### **Acknowledgements**

This study was supported by the Deutsche Forschungsgemeinschaft (SFB 507-A1 (G.C.P., K.M.E.), LA1348/2 (F.v.L.)), and by grants from the NIH (CA46128) and United States Army Medical Research and Development Command Grant (DAMD17-01-1-0670) (P.D.C.). The authors wish to thank Drs. Hauptmann, Harms and Flath (Berlin, Germany) and Bamborschke (Bernau, Germany) for their help in the patient assessment.

Stiff-Person syndrome (Stiff-Man syndrome) is a central nervous disorder characterized by progressive muscular rigidity, superimposed episodic spasms and continuous motor unit activity at rest<sup>2,16</sup>. The majority of patients harbor autoantibodies against glutamic acid decarboxylase (GAD), the rate-limiting enzyme for the synthesis of the inhibitory neurotransmitter  $\gamma$ -aminobutyric acid, in serum and cerebrospinal fluid<sup>23,24</sup>. These and other clinical, pharmacological and electrophysiological findings<sup>14</sup> have led to the hypothesize an autoimmune-mediated impairment of central nervous inhibitory circuits, resulting in tonic firing of  $\alpha$ -motoneurons, as the cause for the disease. Autoreactivity directed against cells expressing GAD can also cause pathology outside the central nervous system, primarily insulin-dependent diabetes mellitus<sup>1,15,24</sup>.

A paraneoplastic etiology, i.e. a disturbance of organ function occurring at a site remote from an underlying neoplasm or its metastases<sup>6</sup>, is thought to underlie about 5% of patients with Stiff-Person syndrome. Even in this case, there is evidence for an autoimmune origin of the neurological symptoms, although autoimmune mechanisms may be different. These patients usually have breast adenocarcinoma<sup>7,10,11</sup> and are positive for autoantibodies against amphiphysin<sup>7,10,11</sup>, a synaptically enriched protein with a putative role in membrane traffic, signalling and actin function<sup>9</sup>. Amphiphysin 1 is expressed only at very low levels outside the brain, but can be overexpressed in breast cancer<sup>10</sup>. In brain, amphiphysin 1 exists primarily as a heterodimer with amphiphysin 2 (neuronal amphiphysin 2 or n-amphiphysin 2), a similar protein encoded by a different gene<sup>9,18,27</sup>. An amphiphysin 2 splice variant (muscle amphiphysin 2 or m-amphiphysin 2, also referred to as Bin1<sup>21,26</sup>) is expressed at very high level in skeletal muscle, where it is thought to function in transverse-tubule physiology<sup>3,12,19</sup>.

Here we report a patient (Pt #1) with breast cancer, paraneoplastic Stiff-Person syndrome and recurrent rhabdomyolysis. We demonstrate that the serum of the patient contains antibodies directed not only against amphiphysin 1, but also amphiphysin 2, suggesting a pathogenetic link between rhabdomyolysis and anti-amphiphysin 2 autoimmunity.

### Case report

A 62-year-old woman was admitted for acute fever, malaise, severe generalized myalgia and dark-coloured urine. Initial laboratory tests revealed hyperkalemia, myoglobinuria and highly elevated serum levels of creatine kinase and myoglobin. She had not taken any medication or recreational drugs. Recent history was negative for infectious diseases or strenuous exercise. Family history was unremarkable. These clinical and laboratory findings led to the diagnosis of rhabdomyolysis of unknown cause. The patient recovered after administration of intravenous fluid and high-dose methylprednisolone over several days.

Recent medical history revealed that three weeks before admission, the patient noticed a progressive rigidity and stiffness of the right proximal leg and lower back that spread to the right calf and foot and to the left leg within two weeks, resulting in bilateral fixed plantar flexion and inversion of feet and toes. She also had episodes of painful spasms in both legs aggravated by sudden noise or emotional upset that disappeared during sleep. Deep tendon reflexes were brisk and symmetrical. Plantar reflexes were flexor. The remaining neurological examination was also unremarkable. Magnetic resonance imaging of the brain and spinal cord was normal. Cerebrospinal fluid examination revealed lymphocytic pleocytosis (82 cells  $\text{cm}^{-3}$ ), an increased IgG index (3.6), oligoclonal bands confined to the cerebrospinal fluid and a protein content of 0.6 g  $\text{l}^{-1}$ . Peripheral and central nervous sensory and motor conduction was within normal limits. Concentric needle electromyography of paraspinal and lower limb muscles showed continuous motor unit activity at rest. Antibodies against GAD were not detected, but serum and cerebrospinal fluid contained high titers of autoantibodies against amphiphysin 1. No other

paraneoplastic antibodies, such as antibodies directed against Yo, Hu, Ri, Ma, were detected. Based on the presence of anti-amphiphysin autoimmunity, a search for an underlying malignancy was initiated and breast cancer was suspected by mammography. Following surgical excision, tumour histopathology revealed poorly differentiated invasive ductal adenocarcinoma with regional lymph node metastasis. Further diagnostic work-up disclosed no evidence for distant metastases. Based on these findings, a diagnosis of paraneoplastic Stiff-Person syndrome was made. The episodes of painful spasms were alleviated shortly after oral treatment with clonazepam and prednisolone. However, six severe episodes of rhabdomyolysis occurred intermittently that were responsive to high-dose intravenous methylprednisolone.

The patient remained wheelchair-bound due to the plantar flexion and rigidity of both legs even after two months of oral medication. Therefore, she was treated with  $400 \text{ mg kg}^{-1}$  intravenous human immunoglobulin per day for five consecutive days, according to the treatment regimen proposed by Dalakas et al.<sup>5</sup>. This resulted in a profound improvement of her rigidity, allowing her to walk again with assistance. Furthermore, rhabdomyolysis ceased to occur. After the patient was discharged for rehabilitation, she continued to improve until she unexpectedly deteriorated with signs of an acute systemic infection. She was admitted to a municipal hospital and died two days later in acute septic shock.

The co-occurrence of rhabdomyolysis and paraneoplastic Stiff-Person syndrome and the remission of both after intravenous immunoglobulin therapy raised the suspicion that autoreactivity against skeletal muscle could be involved. More specifically, we considered the potential presence of autoimmunity directed against amphiphysin 2, an abundant skeletal muscle protein. Therefore, further tests were conducted.

## Methods

Serum samples were obtained before intravenous immunoglobulin therapy was initiated. Specimen of brain, lumbar spinal cord and skeletal muscle were obtained at autopsy. Hematoxylin and eosin (H&E) staining, luxol fast blue-Periodic Acid Schiff (PAS) reaction and Diaminobenzidine (DAB) immunohistochemistry with antibodies against CD3, CD8, CD20, CD68 and GFAP (DAKO, Germany) were performed according to standard protocols. Western blotting of rat tissues, cell transfection, and immunofluorescence of transfected cells were performed as described<sup>3,11,12</sup>. The following rabbit sera were from our lab: CD8, raised against the COOH terminal region of amphiphysin 2 and specific for amphiphysin 2<sup>3</sup>, EVA, raised against exon 7 of amphiphysin 2<sup>26</sup>, and CD9, raised against a short peptide highly conserved in amphiphysin 1 and 2 and equally reactive with amphiphysin 1 and 2<sup>3</sup>. Monoclonal antibodies specific for amphiphysin 2<sup>21</sup> and for the HA epitope (3F10) were from UBI and Roche, respectively. The serum of another patient (Pt #2) with amphiphysin autoimmunity and paraneoplastic Stiff-Person syndrome was from our caseload. For the expression of human amphiphysin isoforms in CHO cells the following cDNA clones were used: Amph1-pCDNA3(HA) (amphiphysin 1), nAmph2-pCDNA3 (n-amphiphysin 2), and mAmph2-pCDNA3 (m-amphiphysin 2).

## Results

### Examination of central nervous tissue and skeletal muscle

At pathological examination the number of motoneurons in the anterior horn of the lumbar spinal cord was moderately reduced. Some of the motoneurons appeared shrunken and eosinophilic with varying degrees of chromatolysis (Figure 1, A). Scattered CD3- and CD8-

positive T-lymphocytes were present in proximity of neuronal cell bodies and axons (Figure 1, B, C). Neither intraneuronal inclusions nor CD20-positive B-lymphocytes nor perivascular lymphocyte cuffing could be observed. The number of CD68-positive microglial cells and macrophages was markedly increased not only within the grey matter but also in the white matter, whereas astrocytic gliosis appeared mild. In a skeletal muscle biopsy, many muscle fibers appeared severely atrophic (Figure 1, D) or were infiltrated by CD68-positive macrophages, indicating rhabdomyolysis (Figure 1, E).

### Detection of autoantibodies

When the serum of the patient was tested against a postnuclear supernatant (PNS) of brain tissue in a western blot assay, the most prominent reactivity was observed with a set of immunoreactive bands in the 120 kDa range (Figure 2, A). An additional set of bands in the 80-90 kDa region were less intensely reactive. Both the upper and lower group of bands comigrated with material recognized by rabbit sera raised against amphiphysin 1 and/or 2 (Figure 2, A). Sera CD8 and EVA are directed against amphiphysin 2, while serum CD9 recognizes equally both proteins (Figure 2, A). These results are consistent with the presence in the serum of Pt #1 of antibodies directed against both amphiphysin 1 and 2. The serum of a previously studied patient (Pt#2), with Stiff-Man syndrome, breast cancer and anti-amphiphysin autoimmunity, produced a very similar western blot pattern (Figure 2, A). Surprisingly, neither Pt #1 serum nor Pt #2 serum produced a detectable signal on amphiphysin 2 when tested by western blotting on skeletal muscle tissue (not shown), in spite of the high expression level in this tissue of m-amphiphysin 2. To clarify this discrepancy, we expressed n- and m- human amphiphysin 2 in CHO cells and tested the two patient sera by western blotting and immunofluorescence on these cells. N- and m-amphiphysin 2 have different molecular weight due to the absence in m-amphiphysin 2 of a neuron-specific insert<sup>3,21,26</sup>. Bin1, a monoclonal antibody raised against amphiphysin 2, demonstrated the expression of appropriate bands at approximately 85 and 60 kDa respectively, while the serum of Pt #1 (and that of Pt #2 used as a control) reacted only with n-amphiphysin 2 (Figure 2, B). In contrast, Pt #1 serum produced a strong fluorescence pattern not only on n-amphiphysin 2 (and amphiphysin 1) expressing cells, but also m-amphiphysin 2 expressing cells (Figure 3). We conclude that Pt #1 serum recognizes only conformational epitopes in m-amphiphysin 2, which are disrupted by the denaturing steps involved in western blotting, but not by the formaldehyde fixation used for immunofluorescence. In agreement with this conclusion, Pt #1 serum only reacted with a pool of m-amphiphysin 2 in transfected cells. It reacted with the diffuse cytosolic pool of the protein but not the linear elements representing amphiphysin 2 coats around tubular invaginations of the plasma membrane induced by its overexpression (Figure 3, insets). The reactivity of Pt #1 serum with n-amphiphysin 2 in western blot assays must reflect the reactivity contributed by the neuron-specific exons of the protein.

### Discussion

We describe here a patient affected by breast cancer, paraneoplastic Stiff-Person syndrome and rhabdomyolysis. The presence of anti-amphiphysin autoimmunity is consistent with an autoimmune origin of the neurological symptoms. In addition, the response of rhabdomyolysis to steroid treatment and immunoglobulin therapy, together with histological examinations, suggest an autoimmune origin of this condition as well. Moreover, we show here that our patient was positive for antibodies that recognize native epitopes of m-amphiphysin 2, a very abundant protein of skeletal muscle, in addition to antibodies reactive with native and denatured epitopes of neuronal amphiphysin isoforms. These findings raise the possibility that an autoimmune process triggered by cancer may have attacked both brain and muscle, thus defining

a new paraneoplastic autoimmune syndrome: breast cancer associated with Stiff-Person syndrome, rhabdomyolysis and anti-amphiphysin autoimmunity. The breast cancer tissue of the patient studied here was not available for biochemical testing. However, the expression of amphiphysin in some cases of breast cancer was documented previously<sup>10</sup>, consistent with a role of this protein in the triggering of autoimmunity.

In earlier reports of paraneoplastic neurological cases associated with anti-amphiphysin autoimmunity, primarily Stiff-Person syndrome or similar conditions, autoantibodies were found to be directed exclusively or primarily against amphiphysin 1<sup>7,10,11</sup>. However, typically, antibodies were searched for by the western blot assays, a method which involves protein antigen denaturation and therefore disrupts reactivity of conformation-sensitive epitopes. Even in the case described here, antibodies revealed by western blotting revealed primarily anti-amphiphysin 1 antibodies. Antibodies directed against amphiphysin 2 were of lower titre and, in the case of m-amphiphysin 2, recognized only native epitopes. Yet, this observation is not inconsistent with a close and direct relationship between anti-amphiphysin autoimmunity and rhabdomyolysis in our patient. A similar situation exists in the case of the association between autoimmunity directed against glutamic acid decarboxylase (GAD), Stiff-Person syndrome and insulin-dependent diabetes mellitus (IDDM). Autoimmunity directed against GAD is the known link between Stiff-Person syndrome and IDDM. However, in most cases of IDDM only anti-GAD antibodies directed against native epitopes are present, while GAD autoantibodies of Stiff-Man syndrome typically react very strongly in western blot assays<sup>1,15</sup>.

Both amphiphysin 1 and 2 are intracellular antigens, and the potential pathogenetic role of anti-amphiphysin autoantibodies remains elusive. A wide variety of other human autoantibodies associated with diseases, including autoantibodies of other paraneoplastic conditions<sup>6</sup>, GAD autoantibodies<sup>1,23</sup> and antibodies found in a variety of organ-specific and systemic autoimmune diseases<sup>4</sup> are also directed against intracellular antigens. Clearly, there is a relationship between the autoantibodies and the specific pathological condition, but the relation may be only indirect. This also explains why the induction of humoral immunity directed against these antigens is not sufficient to elicit disease (for example in experimentally immunized animals) and why not all patients with autoantibodies develop disease or the whole spectrum of diseases that can be associated with a given autoantibody.

Whereas the ability of autoantibodies associated with infectious diseases to precipitate rhabdomyolysis is well known<sup>28</sup>, so far no autoantibodies have been identified in cases of rhabdomyolysis associated with neoplasias<sup>8,13,17,20,22,25</sup>. Anti-amphiphysin 2 autoimmunity may be present in some of these cases. Our study identifies an important, hitherto unrecognized complication in paraneoplastic Stiff-Person syndrome. When associated with Stiff-Person syndrome, rhabdomyolysis may have an autoimmune origin and a paraneoplastic etiology should be considered. It is also possible that paraneoplastic rhabdomyolysis may occur in the absence of Stiff-Person syndrome. Expedient management is critical in rhabdomyolysis, a potentially life-threatening event<sup>28</sup>. Our findings suggest that immunosuppressive or immunomodulatory therapy should be considered in cases associated with Stiff-Person syndrome or with cancer.

Acknowledgments: this work was supported in part by a grant from the NIH (NCI 046128 and from the US Army Medical Research and Materiel Command (USAMRMC) to Pietro De Camilli

## References

1. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P, Camilli PD. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature*. 1990 Sep 13;347(6289):151-6.
2. Brown P, Marsden CD. The stiff man and stiff man plus syndromes. *J Neurol* 1999;246:648-652.
3. Butler MH, David C, Ochoa GC, et al. Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of ranvier in brain and around T tubules in skeletal muscle. *J Cell Biol* 1997;137:1355-1367.
4. Craft J, Solimena M. 1996. Identification of autoantibodies and the antigens they bind. In "Handbook of Experimental Immunology" (5th edition) DM Weir, C Blackwell, L Herzenberger, & L Herzenberg, eds, (Oxford: Blackwell Scientific Publications), pp: 97.1-97.18.
5. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for Stiff-Person syndrome. *N Engl J Med* 2001;345:1870-1876.
6. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. *Brain Pathol* 1999;9:275-284.
7. De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. *J Exp Med* 1993;178:2219-2223.
8. Diez-Martin JL, Lust JA, Witzig TE, Banks PM, Li CY. Unusual presentation of extranodal peripheral T-cell lymphomas with multiple paraneoplastic features. *Cancer* 1991;68:834-841.
9. Di Paolo G, Sankaranarayanan S, Wenk MR, et al. Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. *Neuron* 2002;33:789-804.
10. Floyd S, Butler MH, Cremona O, et al. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. *Mol Med* 1998;4:29-39.
11. Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. *N Engl J Med* 1993;328:546-551.
12. Lee E, Marcucci M, Daniell L, et al. Amphiphysin 2 (bin1) and T-tubule biogenesis in muscle. *Science* 2002;297:1193-1196.
13. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. *Neurology* 1998;50:764-767.

14. Levy LM, Dalakas MC, Floeter MK. The Stiff-Person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. *Ann Intern Med* 1999;131:522-530.
15. Lohmann T, Hawa M, Leslie RD, Lane R, Picard J, Londei M. Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus. *Lancet* 2000;356:31-35.
16. Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm („stiff-man“ syndrome): report of a case and some observations in 13 other cases. *Mayo Clin Proc* 1956;31:421-427.
17. Pillay PK, Estes ML. Acute necrotising myopathy in association with carcinoma of the tongue. *Ann Acad Med Singapore* 1993;22:516-517.
18. Ramjaun AR, Micheva KD, Bouchelet I, McPherson PS. Identification and characterization of a nerve terminal-enriched amphiphysin isoform. *J Biol Chem* 1997;272:16700-16706.
19. Razzaq A, Robinson IM, McMahon HT, et al. Amphiphysin is necessary for organization of the excitation-contraction coupling machinery of muscles, but not for synaptic vesicle endocytosis in *Drosophila*. *Genes Dev* 2001;15:2967-2979.
20. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. *Muscle Nerve* 2000;23:1800-1818.
21. Sakamuro, D, Elliot, KJ, Wechsler-Reya, R, Prendergast, GC. Bin1 is a novel myc-interacting protein with features of a tumor suppressor. *Nat Genet* 1996; 14(1): 69-77.
22. Smith B. Skeletal muscle necrosis associated with carcinoma. *J Pathol* 1969;97:207-210.
23. Solimena M, Folli F, Denis-Donini S, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. *N Engl J Med* 1988;318:1012-1020.
24. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. *N Engl J Med* 1990;322:1555-1560.
25. Sundblad A, Porwit A, Ostad M, et al. Antibody reactivities to skeletal muscle proteins in a patient with lambda light chain secreting multiple myeloma, generalised amyloidosis and rhabdomyolysis. *Eur J Haematol* 2001;67:189-193.
26. Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. *J BiolChem* 1997;272:31453-31458.
27. Wigge P, Vallis Y, McMahon HT. Inhibition of receptor-mediated endocytosis by the amphiphysin SH3 domain. *Curr Biol* 1997;7:554-560.

28. Vanholder R, Sever MS, Ereğ E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000;11:1553-1561.

## Figure legends

Figure 1. Post-mortem histology of the anterior horn of lumbar spinal cord (A-C) and skeletal muscle (D, E). In the anterior horn of the spinal cord, many neurons with signs of eosinophilic degeneration (A, arrow) were observed. Some CD3-positive (B) or CD8-positive (C) T-lymphocytes (arrows) were located in perineuronal or periaxonal positions. Arrowheads indicate neuronal cell bodies. Muscle biopsy shows atrophic muscle fibers (D, arrows) and myophagocytosis (E). Necrotic muscle fibers contain CD68-positive macrophages (E, arrows). H&E x400, DAB immunohistochemistry (brown) (x500).

Figure 2. Western blot analysis of Patient 1 (Pt #1) serum demonstrating presence of anti-amphiphysin antibodies. (A) A rat brain post-nuclear supernatant (PNS) was separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with human sera or antibodies directed against amphiphysin. CD8 and EVA are rabbit polyclonal antibodies raised against amphiphysin 2, and CD9 is a rabbit polyclonal antibody that equally recognizes amphiphysin 1 and 2. Pt #1 serum, like Pt#2 serum, recognize a set of bands which precisely comigrate with amphiphysin 1 and 2 immunoreactivities recognized by the rabbit antibodies. Control = secondary antibody alone. (B) Western blots of CHO cells transfected with neuronal (nAmph2) and muscle (mAmph2) amphiphysin 2 with the sera of Pt #1 and Pt #2 or with the mouse monoclonal antibody Bin1, which recognizes both amphiphysin 2 isoforms. The two human sera recognize n-amphiphysin 2 but not m-amphiphysin 2 in this assay that involves protein denaturation. Naive = untransfected cells.

Figure 3. Patient 1 (Pt #1) serum recognizes native muscle amphiphysin 2. CHO cells were transfected with neuronal or muscle isoforms of human amphiphysin 1 and 2 and then stained by immunofluorescence with the serum of Pt #1 (right) and with antibodies which recognize the transfected protein (left). In all cases, Pt #1 serum recognizes the transfected proteins. Note, however, in the m-amphiphysin 2 transfected cells, that Pt #1 serum does not recognize the linear elements representing m-amphiphysin 2 around membrane tubules (see insets representing higher magnification of regions outlined in rectangles). This observation suggests that only a subset of accessible m-amphiphysin 2 epitopes are labelled by the serum. Control = CHO cells transfected with mAmph2 and stained with secondary antibody only.





Fig. 2





Fig. 3



# Appendix 2

## Quivering phenotype and altered distribution of K<sup>+</sup>-channels in $\beta$ IV spectrin $\Sigma$ 1 KO mice.

**Sandra Lacas-Gervais**<sup>1\*</sup>, Jun Guo<sup>2\*</sup>, Klaus-Peter Knoch<sup>1</sup>, Matthew Rasband<sup>4</sup>, Pietro De Camilli<sup>2</sup> and Michele Solimena<sup>1,3</sup>.

<sup>1</sup>Experimental Center, Medical School Carl-Gustav Carus, Technical University, Dresden, Germany ; <sup>2</sup> Dept Cell Biology , Howard Hughes Medical Institute, Yale University, New Haven, CT, USA <sup>3</sup>Max-Planck-Institute for Molecular Cell Biology and Genetic, Dresden, Germany ; <sup>4</sup>University of Connecticut Health Center, Farmington, USA.

Being required for the proper clustering of ion channels at axon initial segments and nodes of Ranvier of myelinated neurons,  $\beta$ IV spectrin plays an important role in nerve conduction.  $\beta$ IV spectrin has been identified as the main target of autoimmunity in a patient with paraneoplastic lower motor neuron syndrome, which is caused by the destruction of myelinated motoneurons (Berghs *et al*, PNAS, 2001) The  $\beta$ IV spectrin gene undergoes extensive alternative splicing, leading to the expression of at least six isoforms, named  $\Sigma$ 1 to  $\Sigma$ 6. In the quivering mouse spontaneous mutations of several  $\beta$ IV spectrin isoforms cause auditory and motor neuropathies (Parkinson *et al*, Nature Genetics, 2001). To begin addressing the individual role of  $\beta$ IV spectrin isoforms, we generated isoform- specific antibodies and a knock out mouse in which only  $\beta$ IV $\Sigma$ 1 spectrin (250 kD), but not the smaller isoforms (160 kD and 140 kD), is absent. Lack of  $\beta$ IV $\Sigma$ 1 spectrin is sufficient to induce a quivering phenotype. Immunocytochemistry on brain sections shows an enrichment for  $\beta$ IV spectrins at the nuclear envelope of neurons, in addition to the previously reported concentration at axon initial segments and nodes of Ranvier. Staining of the nuclear envelope is not affected in  $\beta$ IV $\Sigma$ 1  $-/-$  mice. On the contrary, immunolabeling is significantly reduced at axon initial segments, while the distribution of K<sup>+</sup> channel in the perinodal region is enlarged. Based on these data we conclude that  $\beta$ IV $\Sigma$ 1 spectrin is the specific isoform localized at axon initial segments and it is required for the restricted distribution of K<sup>+</sup> channels.

\* equal contributors

Abstract to the ELSO Meeting, September 2003, France

# Appendix 3

## **DELETION OF THE SPECIFIC AND PH DOMAINS OF BETA IV SPECTRIN RESULTS IN DISRUPTED NODES OF RANVIER.**

**Y Yang<sup>1</sup>, S Lacas-Gervais<sup>2</sup>, K Morest<sup>1</sup>, M Solimena<sup>2</sup>, MN Rasband<sup>1</sup>**

**<sup>1</sup> Department of Neuroscience**

**University of Connecticut Health Center, Farmington CT 06030-3401**

**<sup>2</sup> Medical School, Technical University Dresden, Dresden, 01307**

**Germany**

The node of Ranvier is a highly polarized structure characterized by the clustering of ion channels, cell adhesion molecules, and adaptor proteins. A recently identified cytoskeletal component beta IV spectrin, was reported at nodes of Ranvier and has been proposed to be involved in targeting and/or stabilizing nodal proteins. Alternative splicing of beta IV spectrin generates at least six isoforms. The longest of these, sigma 1, consists of an N-terminal actin-binding Calponin-homology (CH) domain, followed by 17 spectrin repeats, a 'specific domain' characterized by four ERQES repeats, and finally a C-terminal pleckstrin homology (PH) domain. Of the remaining isoforms, only sigma 3 and 6 are predicted to contain the PH domain. We have examined mice (quivering3J or QV3J) with a mutation in the 'specific domain', resulting in truncation and loss of the PH domain. Homozygous mutant QV3J mice show ataxia that progressively worsens, followed by death at just a few months of age. At many nodes, nodal, paranodal, and juxtaparanodal proteins are delocalized and nodes appear to degenerate. In particular, immunostaining with sodium channel antibodies showed that in the CNS nodal clusters were twice the length of control littermates. Finally, while ultrastructural analysis of 3-4 month old mutant optic nerves showed that transverse bands were present, and myelin appeared to be appropriately compacted, nodes were twice the length found in control mice, with an average length of 1.85 micrometers. Supported by NIH R01NS44916, the Wadsworth Foundation and the A. von Humboldt Foundation.

**Abstract to the Society for Neuroscience Meeting, November 2003**

# Appendix 4

Principal Investigator/Program Director (Last, first, middle):

De Camilli, Pietro

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Pietro De Camilli, M.D.</b>		POSITION TITLE <b>Professor &amp; Investigator</b>	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Lyceum Manzoni, Milan, Italy	Maturita Classica	1996	Liceo Classico
University of Milano School of Medicine, Italy	M.D.	1972	
University of Pavia School of Medicine, Italy	Post Grad.	1975	Medical Endocrinology

### Positions & Honors

1972-1978 Assistant Professor, Department of Medical Pharmacology and CNR Center of Cytopharmacology, University of Milano, Italy  
 1978-1979 Postdoctoral Fellow, Department of Pharmacology (laboratory of Paul Greengard), Yale University School of Medicine  
 1979-1981 Assistant Professor, Section of Cell Biology, Yale University School of Medicine  
 1981-1987 Associate Professor, Department of Medical Pharmacology and CNR Center of Cytopharmacology, University of Milano, Italy  
 1987-1988 Visiting Associate Professor, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York  
 1988-1992 Associate Professor with tenure, Department of Cell Biology, Yale University  
 1997-2000 Chairman, Department of Cell Biology  
 1992-present Professor, Department of Cell Biology; Investigator, Howard Hughes Medical Institute, Yale University School of Medicine

1978 - 1981: Fulbright -Hays Visiting Scholar in Pharmacology (Yale University); 1978: NATO fellowship (declined); 1978: Fellowship from the Muscular Dystrophy Association of America; 1979: Fellowship from the Muscular Dystrophy Association of America; Since 1987: EMBO (European Molecular Biology Organization) member; 1989: Klingenstein Neuroscience Award; 1990: Max-Planck Research Prize (shared with Dr. R. Jahn, Munich); 1991: McKnight Research Project Award; 1995: DATTA Lecturer and Medal Recipient, Federation of European Biochemical Societies (Basel, Switzerland); 1997: Kroc Lecture on Diabetes, University of Washington; 1997: Member of the National Advisory Committee of the Pew Scholars Program for Biochemical Science; Member of the Italian Telethon Scientific Committee; 1997: Keith Porter Lecture, American Society for Cell Biology Meeting (Washington, DC); 2001: Member, American Academy of Arts and Sciences; 2001: Member, American National Academy of Sciences; 2002: Eighth Annual Kenneth F. Naidorf Memorial Lecture, Columbia University (New York, New York); 2002: Alex Novikoff Lecture, 2002 Gordon Conference on Lysosomes (Andover, New Hampshire)

### Publications (Selected Recent Publications)

Rosin L, **De Camilli P**, Butler MH, Solimena M, Schmitt HP, Norgenthaler N, and Meinck HM. 1998. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. *Neurology*. 50: 94-98.  
 Floyd S, Butler MH, Cremona O, David C, Freyberg Z, Zhang A, Solimena M, Tokunaga A, Ishizu H, Tsutsui K, and **De Camilli P**. 1998. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. *Mol. Med.* 4: 29-39.  
 Takei K, Slepnev VI, Haucke V, and **De Camilli P**. 1999. Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. *Nat. Cell Biol.* 1: 33-39.  
 Ferraci F, Fassetta G, Butler MH, Floyd S, Solimena M, and **De Camilli P**. 1999. Autoantibodies to axon initial segments and nodes of ranvier in a case of lower motor neuron disease associated with breast cancer. *Neurology*. 53: 852-855.  
 Haucke V, and **De Camilli P**. 1999. AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic motifs. *Science*. 285: 1268-1271.

- Ringstad N, Gad H, Low P, Di Paolo G, Brodin L, Shupliakov O, and **De Camilli P**. 1999. Endophilin/SH3p4 is required for the transition from early to late stages in clathrin-mediated synaptic vesicle endocytosis. *Neuron*. 24: 143-154.
- Cremona O, Di Paolo G, Wenk M, Luthi A, Kim WT, Takei K, Daniell L, Nemoto Y, Flavell RA, McCormick DA and **De Camilli P**. 1999. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. *Cell*. 99: 179-188.
- Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G, **De Camilli P**, and Solimena M. 2000. Autoimmunity to gephyrin in stiff-man syndrome. *Neuron*. 26: 307-312.
- Solimena M, Butler M and **De Camilli P**. 2000. Autoimmunity in stiff-man syndrome. In *Autoantigens, Autoantibodies, Autoimmunity* (Pabst Science Publishers) (Lengerich-Berlin-Prague-Riga-Vienna-Zagreb), pp 601-610.
- Hyman J, Chen H, Di Fiore PP, **De Camilli P**, and Brunger AT. 2000. Epsin 1 undergoes nucleocytosolic shuttling and its ENTH domain, structurally similar to armadillo and HEAT repeats, interacts with the transcription factor PLZF. *J. Cell Biol.* 149: 537-546.
- Gad H, Ringstad N, Löw P, Kjaerulff O, Gustafsson J, Wenk M, DiPaolo G, Nemoto Y, Crum J, Ellisman MH, **De Camilli P**, Shupliakov O, and Brodin L. 2000. Fission and uncoating of clathrin-coated vesicles at the synapse is perturbed by disruption of interactions with the SH3 domain of endophilin. *Neuron*. 27: 301-312.
- Ochoa GC, Slepnev VI, Neff L, Ringstad N, Takei K, Daniell L, Cao H, McNiven M, Baron R, and **De Camilli P**. 2000. A functional link between dynamin and the actin cytoskeleton at podosomes. *J. Cell Biol.* 150: 377-389.
- Slepnev V, and **De Camilli P**. 2000. Accessory factors in clathrin dependent synaptic vesicle endocytosis. *Nature Neurosci. Rev.* 1: 161-172.
- Solimena M, and **De Camilli P**. 2000. Synaptic autoimmunity and the Salk factor. *Neuron*. 28: 309-316.
- Berghs S, Ferracci F, Maksimova E, Gleason S, Leszczynski N, Butler M, **De Camilli P**, and Solimena M. 2001. Autoimmunity to  $\alpha$ -IV spectrin in paraneoplastic lower motor neuron syndrome. *Proc. Natl. Acad. Sci.* 98: 6945-6950.
- Cremona O, and **De Camilli P**. 2001. Phosphoinositides in membrane traffic at the synapse. *J. Cell Sci.* 114: 1041-1052.
- Chang S, and **De Camilli P**. 2001. Glutamate-mediated regulation of actin-based in axonal filopodia. *Nat. Neurosci.* 8: 787-793.
- Nemoto Y, Wenk MR, Watanabe M, Daniell L, Murakami T, Ringstad N, Yamada H, Takei K, and **De Camilli P**. 2001. Identification and characterization of a synaptotagmin 2 splice isoform predominantly expressed in nerve terminals. *J. Biol. Chem.* 276: 41133-41142.
- Luthi A, Di Paolo G, Cremona O, Daniell L, **De Camilli P**, and McCormick DA. 2001. Stability of GABAergic transmission in primary cultures of cortical neurons: involvement of synaptotagmin 1. *J. Neurosci.* 21: 9101-9111.
- Wenk MR, Pellegrini L, Klenchin VA, Di Paolo G, Chang S, Daniell L, Arioka M, Martin TF, and **De Camilli P**. 2001. PIP kinase  $\alpha$  is the major PI(4,5)P<sub>2</sub> synthesizing enzyme at the synapse. *Neuron*. 32: 79-88.
- Farsad K, Ringstad N, Takei K, Floyd SR, and **De Camilli P**. Generation of high curvature membranes mediated by direct endophilin-bilayer interactions. 2001. *J. Cell Biol.* 155: 193-200.
- De Camilli P**, Chen H, Hyman J, Panepucci E, Bateman A and Brunger AT. 2002. The ENTH Domain. *FEBS Lett.* 513: 1-8.
- Di Paolo G, Sankaranarayanan S, Wenk MR, Daniell L, Perucco E, Caldarone BJ, Flavell R, Picciotto MR, Ryan TA, Cremona O, and **De Camilli P**. 2002. Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. *Neuron*. 33: 789-804.
- Lee K, and **De Camilli P**. 2002. Dynamin at actin tails. *Proc. Natl. Acad. Sci.* 99: 161-166.
- Polo S, Bossi G, Sigismund S, Feretta M, Guidi M, Capuo MR, Bossi G, Chen H, **De Camilli P**, and Di Fiore PP. 2002. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. *Nature*. 416: 451-455.
- Lee E, Marcucci M, Daniell L, Ochoa GC, Farsad K, and **De Camilli P**. 2002. Amphiphysin 2 (BIN1) and T-tubule biogenesis in muscle. *Science*. 297: 1193-1196.
- Di Paolo G, Pellegrini L, Letinic K, Voronov S, Chang S, Wenk MR, and **De Camilli P**. 2002. Recruitment and regulation of PIP kinase type  $\alpha$  by the FERM domain of talin. *Nature*. 420: 88-89.
- Kim W, Chang S, Daniell L, Cremona O, Di Paolo G and **De Camilli P**. 2002. Delayed re-entry of recycling vesicles into the fusion-competent synaptic vesicle pool in synaptotagmin 1 knockout mice. *Proc. Natl. Acad. Sci.* 99: 17143-17148.
- Schmieder K, **De Camilli P**, Solimena M, and Zschenderlein R. 2002. Paraneoplastic stiff person - syndrome with amphiphysin autoantibodies: no tumor progression over five years. *Neurology*. 58: 148.
- Guo J, Wenk MR, Pellegrini L, Onofri F, Benfenati F and **De Camilli P**. 2003. Phosphatidylinositol 4-kinase type II $\alpha$  is responsible for the phosphatidylinositol 4-kinase activity associated with synaptic vesicles. *Proc. Natl. Acad. Sci.* 100: 3995-4000.
- Wenk MR, Lucast L, Di Paolo G, Romanelli AJ, Suchy SF, Nussbaum RL, Cline GW, McMurray W and **De Camilli P**. 2002. Phosphoinositide profiling in complex lipid mixtures using electrospray ionization mass spectrometry. *Nat. Biotech.* In Press.

# Appendix 5

## BIOGRAPHICAL SKETCH

**Michele Solimena, M.D., Ph.D.**

POSITION TITLE  
Professor of Experimental Diabetology, TU-Dresden

### A Education

1979	Lyceum Berchet, Milano, Italy	Degree: "Maturita" (Humanities)
1986	University of Milano School of Medicine, Italy	Degree: M.D. (Medicine)
1993	University of Milano School of Medicine, Italy	Degree: Ph.D. (Pharmacology)

### B. Professional Experience

1986-1988:	Postdoctoral Fellow, Department of Pharmacology, Univ. of Milano, Milano, Italy
1988-1993:	Postdoctoral Fellow, Dept. of Cell Biology, Yale School of Medicine
1994-1999:	Asst. Prof., Dept. of Internal Medicine, Yale School of Medicine
1999-9/2001:	Assoc. Prof., Depts. of Internal Medicine and Cell Biology, Yale School of Medicine
10/2001-12/2002:	Group Leader, Max Planck Institute for Molecular cell Biology and Genetics, Dresden, Germany
01/2003-present	Professor for Experimental Diabetology, Faculty of Medicine, University of Technology Dresden

### Honor and Awards

1987: Trabucchi Fellowship; 1996-1998; 1988: Levi Fellowship, Lincei's National Academy; 1988: Upjohn Prize; 1989: MDA Fellowship; 1990-1991: MDA Sydney-Blackmer Fellowship; 1992-1993: JDF Fellowship; 1994-1996: JDF Career Development Award; 1996-1998: ADA Research Award; 1996-1999: Donaghue Foundation New Investigator Award; 1997: NIH Director's Shannon Award; 1999-2002: ADA Research Award; 2001-2003: Wolfgang Paul Award, Alexander von Humboldt Foundation, Germany.

### C. Selected publications

**Solimena M**, Folli F, Denis-Donini S, Comi G, Pozza G, De Camilli P, Vicari A. 1988. Autoantibodies directed against glutamic acid decarboxylase (GAD) in the cerebrospinal fluid and serum of a patient with Stiff-Man syndrome, epilepsy and type I diabetes mellitus. **New Engl. J. Med.** 318: 1012-20.

Vicari A, Folli F, Pozza G, Comi G, Comola M, Canal N, Besana C, Borri A, Tresoldi M, **Solimena M**, De Camilli P. 1989. Plasmapheresis in the treatment of Stiff-Man syndrome. **New Engl. J. Med.** 320: 1499.

**Solimena M**, Folli F, Aparisi, Pozza G, De Camilli P. 1990. Autoantibodies to GABA-ergic neurons and pancreatic  $\beta$ -cells in Stiff-Man syndrome: a study of 33 cases. **New Engl. J. Med.** 322: 1555-1560.

Baekkeskov S, Aanstoot H-J, Christgau S, Reetz A, **Solimena M**, Cascalho M, Folli F, Richter-Olesen H, and De Camilli P. 1990. The 64kd autoantigen of insulin-dependent diabetes mellitus is the GABA synthesizing enzyme glutamic acid decarboxylase. **Nature** 347: 151-156.

Reetz A, **Solimena M**, Matteoli M, Takei K, Folli F, De Camilli P. 1991. GABA and pancreatic  $\beta$ -cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. **EMBO J.** 10: 1275-1284.

Folli F, **Solimena M**, Cofield R, Austoni M, Tallini G, Fassetta G, Bates D, Cartledge N, Bottazzo GF, Piccolo G, De Camilli P. 1993. Autoimmunity to a 128kD synaptic protein in three women with the Stiff-man syndrome and breast cancer. **New Engl. J. Med.** 328: 546-551.

**Solimena M**, Aggujaro D, Muntzel C, Dirx R, Butler M, De Camilli P, Hayday, A. 1993. Association of GAD65, but not of GAD67, with the Golgi complex is mediated by the NH2 terminal region. **PNAS USA** 90: 3073-3077.

**Solimena M**, De Camilli P. 1993. Spotlight on a neuronal enzyme. **Nature** 372: 15-17.

Butler M, Solimena M, Dirx R, Hayday A, De Camilli P. 1993. Identification of a dominant epitope of glutamic acid decarboxylase (GAD65) recognized by autoantibodies in Stiff-Man syndrome. **J. Exp. Med.** 178: 2097-2106.

De Camilli P, Thomas A, Cofield R, Folli F, Lichte B, Piccolo G, Meinck H-M, Austoni M, Fassetta G, Bottazzo GF, Bates D, Cartledge N, **Solimena M**, and Kilmann MW 1993. The synaptic vesicle-associated protein amphiphysin is the autoantigen of Stiff-Man syndrome with breast cancer. **J. Exp. Med.** 178: 2219-2223.

Pugliese A, **Solimena M**, Awdeh Z, Alper C, Bugawan T, Erlich H, De Camilli P, Eisenbarth GS. 1993. Association of HLA-DQB1\*0201 with Stiff-Man syndrome. **J. Clin. Endocrinol. Metab.** 77: 1550-53.

- Meinck HM, Ricker K, Hulser PJ, Schmid E, Pfeiffer J, **Solimena M**. 1994. Stiff-man syndrome: clinical and laboratory findings in eight patients. **J. Neurol.** 241: 157-166.
- Solimena M**, Dirkx R, Radzynski M, Mundigl O, De Camilli P. 1994. A signal located within a.a. 1-27 of GAD65 is responsible for its targeting to the Golgi complex region. **J. Cell Biol.** 126:331-341.
- David C, **Solimena M**, De Camilli P. 1994. Autoimmunity to Stiff-man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein homologous to the yeast proteins Rvs167 and Rvs161. **FEBS Lett.** 351:73-9.
- Pugliese A, Eisenbarth GS, De Camilli P, **Solimena M**. 1994. Genetics of susceptibility and resistance to insulin-dependent diabetes mellitus in stiff-man syndrome. **Lancet.** 144:1027-1028.
- Solimena M**, De Camilli. 1995. Coxsackieviruses and diabetes. **Nature Med.** 1: 25-26.
- Dirkx R, Thomas A, Li L, Lernmark Å, Sherwin R, De Camilli P, **Solimena M**. 1995. Targeting of the 67 kd isoform of glutamic acid decarboxylase (GAD67) to intracellular organelles is mediated by its interaction with the NH2-terminal region of the 65 kd isoform of glutamic acid decarboxylase (GAD65). **J. Biol. Chem.** 270: 2241-2246.
- Meinck HM, Ricker K, Hulser R, **Solimena M**. 1995. Stiff-man syndrome: neurophysiological findings in eight patients. **J. Neurol.** 242:134-42.
- Solimena M**, Dirkx R, Hermel J-M, Pleasic-Williams S, Shapiro JA, Rabin DU. 1996. The receptor-type phosphatase like protein ICA 512 is an ubiquitous intrinsic membrane protein of neuroendocrine secretory granules. **EMBO J.** 15:2102-14.
- Solimena M**, De Camilli, P. 1996. From Th1 to Th2: diabetes immunotherapy shifts gears. **Nature Med.** 2: 1311-12.
- Bult A, Zhao F, Dirkx R, Sharma E, **Solimena M**, Naegele JR, Lombroso PJ. 1996. STEP<sub>61</sub>: A member of a family of brain-enriched PTPs is localized to the endoplasmic reticulum. **J. Neurosci.** 16: 7821-31.
- Khachatryan A, Guerder S, Palluault F, Cote G, **Solimena M**, Valentijn K, Millet I, Flavell RA, Vignery A. 1997. Targeted expression of the neuropeptide calcitonin gene related peptide to beta cells prevents diabetes in NOD mice. **J. Immunol.** 158: 1409-1416.
- Bult A, Zhao F, Dirkx R, Raghunathan A, **Solimena M**, Lombroso PJ. 1997. STEP: A family of brain enriched PTPs: alternative splicing produces transmembrane, cytosolic and truncated isoforms. **Eur. J. Cell Biol.** 72: 337-344.
- Rosin L, De Camilli P, Butler M, **Solimena M**, Bastert G, Schmitt H-P, Morgenthaler N, Döderlein G, H-M Meinck. 1998. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. **Neurology** 50: 94-98.
- Zekzer D, Wong S, Ayalon O, Millet I, Altieri, M, Shintani, S, **Solimena M**, Sherwin, RS. 1998. GAD reactive CD4<sup>+</sup> Th1 cells induces diabetes in NOD/SCID mice. **J. Clin. Invest.** 101: 68-73.
- Floyd S, Butler MH, Cremona O, David C, Freyberg Z, Zhang A, **Solimena M**, Tsutsui K, De Camilli P. 1998. Enhanced expression of amphiphysin in breast cancer. **Mol. Medicine** 4: 29-39.
- Lee MS, Dirkx R, **Solimena M**, Dannies PS. 1998. Stabilization of the receptor protein tyrosine phosphatase like protein ICA512 in GH4C1 cells upon treatment with estradiol, insulin and EGF. **Endocrinology** 139: 2727-2733.
- Geng L, **Solimena M**, Flavell RA, Sherwin RS, Hayday H. 1998. Widespread expression of an autoantigen-GAD65 transgene does not tolerate NOD mice, and can exacerbate disease. **PNAS USA** 95: 10055-10060.
- Schmierer K, Valdueza JM, Bender A, De Camilli P, David C, **Solimena M**, Zschenderlein R. 1998. Stiff-man syndrome with spinal MRI findings, amphiphysin autoantibodies and immunosuppressive treatment. **Neurology** 51: 250-252.
- Saginario C, Sterling D, Beckers C, Kobayashi R, **Solimena M**, Ullu E, Vignery A. 1998. MFR, a putative receptor mediating the fusion of macrophages. **Mol. Cell Biol.** 18: 6213-23.
- Solimena M**. 1998. Vesicular autoantigens of type I diabetes. 1998. **Diabetes Metabolism Review** 14: 227-240.
- Pugliese A, Kawasaki E, Zeller M, Yu L, **Solimena M**, Moraes C, Ricordi C, Erlich HA, Eisenbarth GS. 1999. Sequence analysis of the type I diabetes-protective HLA-DQB1\*0602 and DQA1\*0102 alleles in unaffected islet cell antibody-positive first degree relatives. **J. Clin. Endocrinol. Metab.** 84:1722-1728.
- Hermel J-M, Dirkx R, **Solimena M**. 1999. Post-translational modifications of ICA512, a receptor protein tyrosine phosphatase like-protein of secretory granules. **Eur. J. Neurosci.** 11: 2609-2620.
- Ferracci F, Fassetta G, Butler, MH, Floyd S, **Solimena M**, De Camilli P. 1999. Autoantibodies to axon initial segments and nodes of Ranvier in a case of lower motor neuron disease associated with breast cancer. **Neurology** 53:852-855.
- Butler MH, Hayashi A, Ohkoshi N, C. Villmann, C.-M. Becker, Feng G, De Camilli P, **Solimena M**. 2000. Autoimmunity to gephyrin in Stiff-Man Syndrome. **Neuron** 26: 307-312.
- Ort T, Maksimova E, Dirkx R, Kachinsky A, Berghs S, Froehner S, **Solimena M**. 2000. The receptor tyrosine phosphatase like-protein ICA512 binds the PDZ domains of  $\beta$ 2-syntrophin and nNOS in pancreatic  $\beta$ -cells. **Eur. J. Cell Biol.** 79, 621-630.

- Solimena M**, Butler M, De Camilli P. 2000. Autoimmunity in Stiff-Man syndrome. 2000. In: "Autoantigens, Autoantibodies, Autoimmunity". K. Conrad, ed, Lengerich: Pabst Science Publishers, pp. 601-610.
- Berghs S, Aggujaro D, Dirckx R, Stabach P, Hermel J-H, Maksimova E, Zhang J-P, Philbrick W, Slepnev V, Ort T, **Solimena M**. 2000.  $\beta$ IV spectrin, a new spectrin localized at axon initial segments and nodes of Ranvier in the central and peripheral nervous system. **J. Cell Biol.** 27: 985-1002.
- Solimena M**, and De Camilli, P. 2000. Synaptic autoimmunity and the Salk factor. **Neuron** 28:309-310.
- Meinck H-M, Maile S, Faber L, Morgenthaler N, Seissler J, Butler M, **Solimena M**, DeCamilli P, Scherbaum WA. 2001. Antibodies against glutamic acid decarboxylase (GAD)- prevalence in neurological diseases. **J. Neurol. Neurosurg. Psych.** 71:100-103.
- Berghs S, Ferracci F, Maksimova E, Gleason S, Leszczynski N, Butler M, De Camilli P, **Solimena M**. 2001. Autoimmunity to  $\beta$ IV spectrin in paraneoplastic lower motor neuron syndrome. **PNAS USA** 98:6945-6950.
- Ort T, Voronov S, Guo J, Zawalich K, Froehner S, Zawalich W, **Solimena M**. 2001. Dephosphorylation of  $\beta$ 2-syntrophin and  $\text{Ca}^{2+}$ /calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. **EMBO J** 20:4013-4023.
- Schmierer K, Grosse P, De Camilli P, Solimena M, Floyd S, Zschenderlein R 2002. Paraneoplastic stiff-person syndrome-no tumor progression over five years. **Neurology** 58: 148.
- Pietropaolo M, James SL, Trucco, Spitzenberger F, Friday RP, Brown D, Stassi G, Giannoukakis N, **Solimena M**, Pugliese A, and Trucco M. 2002. Selective expression of diabetes-related islet autoantigen ICA69 in thymic and peripheral lymphoid cells. **Endocrinology**. (in revision).
- Murinson B, Butler MH, Guarnaccia J, Marek K, Marfurt K, Gleason S, Meinck H-M, De Camilli P, **Solimena M**. 2002. Clinical characteristics and GAD antibody status in 566 patients with a presumed diagnosis of SMS A **Neurol.** (submitted).
- Spitzenberger F, Pietropaolo S, Verkade P, Habermann B, Lacas-Gervais S, Mziaut H, Pietropaolo M, and **Solimena M**. 2002. ICA69 is an arfaptin-related protein associated with the Golgi complex and immature secretory granules of insulinoma INS-1 cells. **J Cell Biol.** (in press).
- Solimena M** and Gerdes H-M. 2003. And the Last will be the First... **Trends Cell Biol.** (in press)
- Knoch K-P, Bergert H, Altkrüger A, Verkade P and **Solimena M**. 2003. Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis (manuscript in preparation).
- Lacas-Gervais S, Guo J, Knoch K-P, Rasband M, De Camilli P and **Solimena M**. 2003. Deletion of  $\beta$ IVS1 spectrin alters the organization of nodes of Ranvier and is sufficient to produce the quivering phenotype in mice (manuscript in preparation).